
Sign up to save your podcasts
Or
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org
4.7
272272 ratings
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org
131 Listeners
323 Listeners
46 Listeners
493 Listeners
3,318 Listeners
14 Listeners
1,083 Listeners
21 Listeners
186 Listeners
513 Listeners
132 Listeners
348 Listeners
182 Listeners
366 Listeners
77 Listeners